Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
Public ClinicalTrials.gov record NCT03453619. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study to Evaluate the Safety and Biologic Activity of APL- 2 in Patients With IgA Nephropathy, Lupus Nephritis, Primary Membranous Nephropathy, or C3 Glomerulopathy (C3 Glomerulonephritis and Dense Deposit Disease)
Study identification
- NCT ID
- NCT03453619
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Apellis Pharmaceuticals, Inc.
- Industry
- Enrollment
- 21 participants
Conditions and interventions
Conditions
Interventions
- APL-2 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 25, 2018
- Primary completion
- Apr 15, 2020
- Completion
- Aug 25, 2023
- Last update posted
- Feb 12, 2025
2018 – 2023
United States locations
- U.S. sites
- 17
- U.S. states
- 14
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Stanford University | Stanford | California | 94305 | — |
| Children's Hospital Colorado | Aurora | Colorado | 80045 | — |
| HealthONE Physician Care, Rocky Mountain Hospital for Children | Denver | Colorado | 80205 | — |
| Washington Nephrology Associates | Washington D.C. | District of Columbia | 20037 | — |
| Horizon Research Group | Coral Gables | Florida | 33134 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| American Research LLC | Jeffersonville | Indiana | 47130 | — |
| Northwest Louisiana Nephrology LLC | Shreveport | Louisiana | 71101 | — |
| Washington Nephrology Associates | Takoma Park | Maryland | 20912 | — |
| Clinical Research Consultants | Kansas City | Missouri | 64111 | — |
| Davita Clinical Research | The Bronx | New York | 10461 | — |
| Westchester Medical Center | Valhalla | New York | 10595 | — |
| Southeastern Nephrology Associates | Wilmington | North Carolina | 28401 | — |
| University Clinical Health | Memphis | Tennessee | 38103 | — |
| Washington Nephrology Associates | Alexandria | Virginia | 22304 | — |
| Davita Clinical Research | Chesapeake | Virginia | 23320 | — |
| Milwaukee Nephrologists | Wauwatosa | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03453619, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 12, 2025 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03453619 live on ClinicalTrials.gov.